Abstract
We review the published literature on migraine with prolonged aura (PA), specifically with regards to the phenotype and treatment options. PA is not uncommon. A recent study found that about 17% of migraine auras are prolonged and that 26% of patients with migraine with aura have experienced at least one PA. The characteristics of PA are similar to most typical auras with the exception of a higher number of aura symptoms (in particular sensory and/or dysphasic). There are no well-established treatments at present which target the aura component of migraine. Other than case reports, there have been open-label studies of lamotrigine and greater occipital nerve blocks. The only randomised, blinded, controlled trial to date has been of nasal ketamine showing some reduction in aura severity but not duration. A small open-labelled pilot study of amiloride was also promising. Larger randomised, controlled trials are needed to establish whether any of the existing or novel compounds mentioned are significantly effective and safe.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ICHD:
-
International Classification of Headache Disorders
- PA:
-
Prolonged aura
- NHMA:
-
Non-hemiplegic migraine aura
- PNHMA:
-
Prolonged non-hemiplegic migraine aura
- PHMA:
-
Prolonged hemiplegic migraine aura
- FHM:
-
Familiar hemiplegic migraine
- SHM:
-
Sporadic hemiplegic migraine
- CSD:
-
Cortical spreading depression
References
Afridi SK, Giffin NJ, Kaube H, Goadsby PJ (2013) A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80(7):642–647. https://doi.org/10.1212/WNL.0b013e3182824e66
Artto V, Nissila M, Wessman M et al (2007) Treatment of hemiplegic migraine with triptans. Eur J Neurol 14(9):1053–1056. https://doi.org/10.1111/j.1468-1331.2007.01900.x
Athwal BS, Lennox GG (1996) Acetazolamide responsiveness in familial hemiplegic migraine. Ann Neurol 40(5):820–821. https://doi.org/10.1002/ana.410400526
Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59(4):652–661. https://doi.org/10.1002/ana.20778
Bates D, Ashford E, Dawson R, Ensink FBM, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P, Sumatriptan Aura Study Group (1994) Subcutaneous sumatriptan during the migraine aura. Neurology 44(9):1587–1592. https://doi.org/10.1212/WNL.44.9.1587
Battistini SS, Tenirri S, Piatti M et al (1999) A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia. Neurology 53(1):38–43. https://doi.org/10.1212/WNL.53.1.38
Bento MS, Esperança P (2000) Migraine with prolonged aura. Headache 40(1):52–53. https://doi.org/10.1046/j.1526-4610.2000.00010.x
Bhatia R, Desai S, Tripathi M, Garg A, Padma MV, Prasad K, Singh MB (2008) Sporadic hemiplegic migraine: report of a case with clinical and radiological features. J Headache Pain 9(6):385–388. https://doi.org/10.1007/s10194-008-0067-1
Bogdanov VB, Multon S, Chauvel V, Bogdanova OV, Prodanov D, Makarchuk MY, Schoenen J (2011) Migraine preventive drugs differently affect cortical spreading depression in the rat. Neurobiol Dis 41(2):430–435. https://doi.org/10.1016/j.nbd.2010.10.014
Cuadrado ML, Aledo-Serrano A, Lopez-Ruiz P, Gutierrez-Viedma A, Fernandez C, Orviz A, Arias JA (2016) Greater occipital nerve block for the acute treatment of prolonged or persistent migraine aura. Cephalalgia 37(8):812–818. https://doi.org/10.1177/0333102416655160
De Cunto A, Bensa M, Tonelli A (2012) A case of familial hemiplegic migraine associated with a novel ATP1A2 gene mutation. Pediatr Neurol 47(2):133–136. https://doi.org/10.1016/j.pediatrneurol.2012.04.012
De Sanctis et al (2011) Prolonged sporadic hemiplegic migraine associated with a novel de novo missense ATP1A2 gene mutation. Headache 51(3):447–450. https://doi.org/10.1111/j.1526-4610.2010.01793.x
Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800
Hansen JM, Hauge AW, Olesen J, Ashina M (2010) CGRP triggers migraine like attacks in patients with migraine with aura. Cephalalgia 30(10):1179–1186. https://doi.org/10.1177/0333102410368444
Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J (2009) Effects of Tonabersat on migraine with aura: a randomized, double-blind, placebo controlled crossover study. Lancet Neurol 8:718–723
Headache Classification Committee of The International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl 7):1–96
Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629–808. https://doi.org/10.1177/0333102413485658
Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders (2nd edn). Cephalalgia 24(Suppl 1):1–160
Ho TW, Connor KM, Zhang Y et al (2014) Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 18:958–966
Holland PR, Akerman S, Andreou AP, Karsan N, Wemmie JA, Goadsby PJ (2012) Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol 72:559–563
Hsu DA, Stafstrom CE, Rowley HA, Kiff JE, Dulli DA (2008) Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil. Brain Dev 30:86–90
Karsan N, Goadsby PJ (2015) CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 15(5):25. https://doi.org/10.1007/s11910-015-0547-z
Kaube H, Herzog J, Käufer T, Dichgans M, Diener HC (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55:139–141
Klapper J, Mathew N, Nett R (2001) Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache 41(10):981–984. https://doi.org/10.1046/j.1526-4610.2001.01192.x
Koch HJ, Sykora A, Hausn P (2010) Off-label use of acetazolamide in a patient with familial hemiplegic migraine and concomitant psychotic episodes. Psychiatr Prax 37(03):148–151. https://doi.org/10.1055/s-0029-1223464
Kors E (2003) Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation: a description of 5 families with familial hemiplegic migraine. Arch Neurol 60(5):684–688. https://doi.org/10.1001/archneur.60.5.684
Kowacs PA, Piovesan EJ, Tatsui CE, Lange MC, Ribas LC, Werneck LC (1999) Prolonged migraine aura without headache arrested by sumatriptan. A case report with further considerations. Cephalalgia 19(4):241–242. https://doi.org/10.1046/j.1468-2982.1999.019004241.x
Lai CW, Ziegler DK, Lansky LL, Torres F (1982) Hemiplegic migraine in childhood: diagnostic and therapeutic aspects. J Pediatr 101(5):696–699. https://doi.org/10.1016/S0022-3476(82)80293-X
Lampl C, Katsarava Z, Diener HC, Limmroth V (2005) Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 76(12):1730–1732. https://doi.org/10.1136/jnnp.2005.063750
Lebas A, Guyant-Marechal L, Hannequin D et al (2008) Severe attacks of familial hemiplegic migraine, childhood epilepsy and ATP1A2 mutation. Cephalalgia 28(7):774–777. https://doi.org/10.1111/j.1468-2982.2008.01603.x
Leo L, Gherardini L, Barone V, De Fusco M, Pietrobon D, Pizzorusso T, Casari G (2011) Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. PLoS Genet 7:e 1002129
Marcus R, Goadsby PJ, Dodick D et al (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114–125
Mohamed BP, Goadsby PJ, Prabhakar P (2012) Safety and efficacy of flunarizine in childhood migraine: 11 years’ experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol 54(3):274–277. https://doi.org/10.1111/j.1469-8749.2011.04154.x
Olesen J, Diener HC, Schoenen J, Hettiarachchi J (2004) No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 11(10):671–677. https://doi.org/10.1111/j.1468-1331.2004.00914.x
Omata T, Takanashi J, Wada T et al (2011) Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. Brain and Development 33(4):332–334. https://doi.org/10.1016/j.braindev.2010.05.006
Pascual J, Caminero AB, Mateos V, Roig C, Leira R, Garcia-Monco C, Lainez MJ (2004) Preventing disturbing migraine aura with lamotrigine: an open study. Headache 44(10):1024–1028. https://doi.org/10.1111/j.1526-4610.2004.04198.x
Pelzer N, Stam AH, Carpay JA, Vries BD, van den Maagdenberg AM et al (2014) Familial hemiplegic migraine treated by sodium valproate and lamotrigine. Cephalalgia 34(9):708–711. https://doi.org/10.1177/0333102413520086
Pfaffenrath V, Kommissari I, Pöllmann W, Kaube H, Rath M (1991) Cerebrovascular risk factors in migraine with prolonged aura and without aura. Cephalalgia 11(6):257–261. https://doi.org/10.1046/j.1468-2982.1991.1106257.x
Pye S, Ahmed M (2014) Duration of migraine aura. Cephalalgia 34(3):236. https://doi.org/10.1177/0333102413500729
Rashidy-Pour A, Motaghed-Larijani Z, Bures J (1995) Tolerance to ketamine-induced blockade of cortical spreading depression transfers to MK-801 but not to AP5 in rats. Brain Res 693(1-2):64–69. https://doi.org/10.1016/0006-8993(95)00692-J
Rothrock JF (1997) Successful treatment of persistent migraine aura with divalproex sodium. Neurology 48(1):261–262. https://doi.org/10.1212/WNL.48.1.261
Rozen T (2003) Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulphate. Headache 43(8):901–903. https://doi.org/10.1046/j.1526-4610.2003.03170.x
Rozen TD, Shanske S, Otaegui D, Lu J, Young WB, Bradley K, DiMauro S, Silberstein SD (2004) Study of mitochondrial DNA mutations in patients with migraine with prolonged aura. Headache 44(7):674–677. https://doi.org/10.1111/j.1526-4610.2004.04126.x
Russel MB, Ducros A (2011) Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 10(5):457–470. https://doi.org/10.1016/S1474-4422(11)70048-5
Silva VB, Inàcio N, Simoes R et al (2010) Prolonged migraine auras. J Headache Pain 11:S79
Steiner TJ, Findley LJ, Yuen AW (1997) Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17(2):109–112. https://doi.org/10.1046/j.1468-2982.1997.1702109.x
Thomsen LL, Olesen J (2004) Sporadic hemiplegic migraine. Cephalalgia 24(12):1016–1024. https://doi.org/10.1111/j.1468-2982.2004.00788.x
Tobita M, Hino M, Ichikawa N, Takase S, Ogawa A (1987) A case of hemiplegic migraine treated with flunarizine. Headache 27(9):487–488. https://doi.org/10.1111/j.1526-4610.1987.hed2709487.x
Van den Maagdenberg, Pizzorusso T, Kaja S, Terpolilli N, Shapovalova M et al (2010) High cortical spreading depression susceptibility and migraine associated symptoms in Cav2.1 S218L mice. Ann Neurol 67(1):85–98. https://doi.org/10.1002/ana.21815
Viana M, Sprenger T, Andelova M, Goadsby PJ (2013) The typical duration of migraine aura: a systematic review. Cephalalgia 33(7):483–490. https://doi.org/10.1177/0333102413479834
Viana M, Linde M, Sances G, Ghiotto N, Guaschino E, Allena M, Terrazzino S, Nappi G, Goadsby PJ, Tassorelli C (2015) O011. Patients with “prolonged aura” do not show clinical or demographic differences from the patients with “typical aura”. J Headache Pain 16(Suppl 1):A67. https://doi.org/10.1186/1129-2377-16-S1-A67
Viana M, Sances G, Ghiotto N, Guaschino E, Allena M, Nappi G, Goadsby PJ, Tassorelli C (2016a) Variability of the characteristics of a migraine attack within patients. Cephalalgia 36(9):825–830. https://doi.org/10.1177/0333102415613612
Viana M, Linde M, Sances G, Ghiotto N, Guaschino E, Allena M, Nappi G, Goadsby PJ, Tassorelli C (2016b) Migraine aura symptoms: duration, succession and temporal relationship to headache. Cephalalgia 36(5):413–421. https://doi.org/10.1177/0333102415593089
Viana M, Sances G, Linde M, Ghiotto N, Guaschino E, Allena M, Terrazzino S, Nappi G, Goadsby PJ, Tassorelli C (2017a) Clinical features of migraine aura: results from a prospective diary-aided study. Cephalalgia 37(10):979–989. https://doi.org/10.1177/0333102416657147
Viana M, Sances G, Linde M, Nappi G, Goadsby PJ, Tassorelli C (2017b) EP-02-024 Prolonged migraine aura: new insights from a prospective diary-aided study. Cephalalgia 37(Suppl 1):189. https://doi.org/10.1177/0333102417719574
Voss T, Lipton RB, Dodick DW et al (2016) A phase IIb randomized, doubleblind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36:887–898
Wahl M, Schilling L, Parsons AA, Kaumann A (1994) Involvement of CGRP and NO in the pial artery dilatation elicited by cortical spreading depression. Brain Res 637:2004–2010
Yu W, Horowitz SH (2001) Familial hemiplegic migraine and its abortive therapy with intravenous verapamil. Neurology 57(9):1732–1733. https://doi.org/10.1212/WNL.57.9.1732
Yu W, Horowitz SH (2003) Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 60(1):120–121. https://doi.org/10.1212/01.WNL.0000042051.16284.70
Funding
This work was supported by grants of the Italian Ministry of Health to RC 2013-2015.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Viana, M., Afridi, S. Migraine with prolonged aura: phenotype and treatment. Naunyn-Schmiedeberg's Arch Pharmacol 391, 1–7 (2018). https://doi.org/10.1007/s00210-017-1438-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-017-1438-4